What question did this study set out to answer?

This research aims to develop a lipid nanoparticle platform that efficiently delivers CRISPR/Cas9 components for precise genomic integration of the CFTR gene.

May 7, 2026

Lipid Nanoparticles for the Delivery of CRISPR/Cas9 Machinery to Enable Site‐Specific Integration of CFTR and Mutation‐Agnostic Disease Rescue (Adv. Funct. Mater. 36/2026)

Key Points

This research aims to develop a lipid nanoparticle platform that efficiently delivers CRISPR/Cas9 components for precise genomic integration of the CFTR gene.
Developed lipid nanoparticles capable of delivering CRISPR/Cas9 components, including mRNA, guide RNA, and DNA templates.
Configured the platform for site-specific integration at the endogenous CFTR locus.
Achieved successful delivery of CRISPR/Cas9 machinery resulting in effective integration of the CFTR gene.
Enabled correction of the cystic fibrosis disease phenotype through targeted gene editing.

Abstract

Lipid Nanoparticles In their Research Article (10.1002/adfm.202502540), Steven J. Jonas and co-workers present a lipid nanoparticle (LNP) platform capable of delivering CRISPR/Cas9 machinery configured to achieve site-specific genomic integration of a full length copy of the CFTR gene at its endogenous locus, enabling rescue of the cystic fibrosis disease phenotype. The cover image illustrates LNPs being packaged with gene editing reagents, including mRNA encoding the Cas9 protein, guide RNA, and linear double stranded DNA donor templates used for this mutation agnostic gene correction strategy. The resulting nanoparticles offer a modular platform for the non-viral correction of inherited diseases.

Bookmark

Cite This Study

Foley et al. (Fri,) studied this question.

synapsesocial.com/papers/69fc2b158b49bacb8b3476ef https://doi.org/https://doi.org/10.1002/adfm.75501

Bookmark